Khadija Saeed

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Dow Jones slips 167 points on AI disruption fears; Alphabet, Amazon earnings next

Dow Jones slips 167 points on AI disruption fears; Alphabet, Amazon earnings next

The Dow Jones Industrial Average dropped 166.67 points Tuesday, closing down 0.34% at 49,240.99 as tech and software stocks came under pressure amid renewed worries about AI squeezing profit margins. “We’re seeing a lot of software companies across the spectrum get hit,” said Art Hogan, chief market strategist at B. Riley Wealth. The S&P 500 fell 0.84% to 6,917.81, while the Nasdaq slid 1.43% to 23,255.19. Merck bucked the trend, rising 2.2% after reporting results, and PepsiCo surged 4.9% following announcements of price cuts on brands like Lay’s and Doritos.
Tesla stock barely moves after-hours as $41,990 Model Y AWD debuts — what TSLA traders watch next

Tesla stock barely moves after-hours as $41,990 Model Y AWD debuts — what TSLA traders watch next

Tesla’s stock barely moved in after-hours trading Tuesday, shortly after the company unveiled a new all-wheel-drive Model Y variant priced at $41,990 on its U.S. website. Shares ticked up 0.1% to $421.83, having fluctuated between $413.69 and $428.42 during the day. Rivian dipped 0.2%, while Lucid climbed 2.0%. This launch comes on the heels of Tesla’s October introduction of cheaper “Standard” Model Y and Model 3 versions, roughly $5,000 less than previous base prices, following the September expiration of the $7,500 federal EV tax credit under the Trump administration. Analysts caution that a shift toward more affordable models could squeeze margins, or profit per car.
Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch

Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch

Shares of Abbott Laboratories dipped 0.6% to $108.77 Tuesday afternoon after the U.S. Food and Drug Administration issued a warning letter to Abbott Diabetes Care. The letter, dated Jan. 23, criticized the company’s process for verifying the accuracy of its FreeStyle Libre continuous glucose monitors. Specifically, the FDA said Abbott failed to ensure key accuracy specs were passed to third-party manufacturers and released finished devices without conducting accuracy tests at launch. Abbott has 15 business days to respond. Earlier, the stock had fallen as much as 2.9%.
3 February 2026
1 318 319 320 321 322 893
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Taiwan Semiconductor

NYSE: TSM 96 / 100
#2 BUY

AerCap

NYSE: AER 95 / 100
#3 BUY ON PULLBACK

Constellation Energy

NASDAQ: CEG 93 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

American International Group

NYSE: AIG 87 / 100
View full portfolio
Editorial model selection. Not personalised advice.